Arthritis, Psoriatic

Dermatology·MeSH: Arthritis, Psoriatic

Prevalence

133.0 / 100K

Incidence

6.0 / 100K/yr

10 drugs in development·6 companies·11 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
Brenzys (SB4)	Organon & Co. (OGN)
Hadlima (SB5)	Organon & Co. (OGN)

Phase 3(3)

Drug	Company
Guselkumab	Crinetics Pharmaceuticals, Inc. (CRNX)
icotrokinra	GH Research PLC (GHRS)
Risankizumab	MoonLake Immunotherapeutics (MLTX)

Phase 2(2)

Drug	Company
allocetra	Enlivex Ltd. (ENLV)
jnj-88545223	GH Research PLC (GHRS)

Phase 1(1)

Drug	Company
Sonelokimab	MoonLake Immunotherapeutics (MLTX)

Phase 4(2)

Drug	Company
guselkumab	JOHNSON & JOHNSON (JNJ)
guselkumab	GH Research PLC (GHRS)

BioSniper tracks 10 drugs in development for Arthritis, Psoriatic across 6 companies.

There are 11 clinical trials targeting Arthritis, Psoriatic tracked by BioSniper.

The estimated prevalence of Arthritis, Psoriatic is approximately 133.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.